What Zevra Therapeutics, Inc. told the SEC could break it.

Zevra is highly dependent on one product — approximately 82% of its 2025 revenue came from commercial sales of MIPLYFFA (arimoclomol), indicated for Niemann-Pick disease type C, a rare disease with a limited patient population — and expects MIPLYFFA to remain its main revenue source; any loss of MIPLYFFA revenue (competition, reimbursement, safety or supply) would materially harm the business.

“For the year ended December 31, 2025 we derived approximately 82% of our revenues from commercial sales of MIPLYFFA® (arimoclomol), which is indicated for a rare disease with a limited patient population.”

Zevra has no manufacturing facilities and procures approved products and bulk drug substances from a limited number of — in some cases sole-source — third-party suppliers, and relies on a single specialty pharmacy to distribute MIPLYFFA; an inability of a sole-source supplier or its sole distribution partner to meet requirements could interrupt supply and materially harm the business.

“We rely on a limited number of suppliers, in some cases sole-source suppliers. We do not have any manufacturing facilities. We procure approved products and bulk drug substances from sole-source, third-party suppliers.”

Zevra has had recurring negative net operating cash flows throughout its history and cannot predict when (or if) it will consistently generate positive operating cash flow; its Term Loans are secured by a first-priority lien on substantially all of its and certain subsidiaries' assets with customary covenant/default provisions, and it relies on equity financing (a $75M ATM, public offerings), creating leverage and funding risk despite a one-time $148.3M priority-review-voucher sale.

“The Term Loans are secured by a first priority perfected lien on, and security interest in, substantially all of our and certain of our subsidiaries' current and future assets.”

Zevra depends on FDA and EMA regulatory approvals — its arimoclomol EU Marketing Authorization Application is under EMA review — and even with approval faces U.S. drug-pricing pressure from the Inflation Reduction Act (Medicare price negotiation, Part B/D inflation rebates) and the American Rescue Plan's removal of the Medicaid drug-rebate cap, which could reduce the prices and reimbursement it can obtain.

“the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare, with prices that can be subject to a cap, imposes rebates under Medicare Part B and Medicare Part D to penalize price in”